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It is currently not known which level of
pentagastrin-stimulated calcitonin serum concentration
indicates medullary thyroid carcinoma in patients with
chronic kidney disease (CKD). We examined CKD stage 3–5
patients who had total thyroidectomy because of a
pentagastrin-stimulated calcitonin concentration greater
than 100 pg/ml, and tested the diagnostic performance of
basal and pentagastrin-stimulated calcitonin levels for
differentiating medullary thyroid carcinoma and C-cell
hyperplasia in this patient population. A total of 180 CKD
patients presented with an elevated calcitonin level and had
a pentagastrin stimulation test. Forty patients showed a
maximum pentagastrin-stimulated calcitonin concentration
greater than 100 pg/ml, and 22 patients had a total
thyroidectomy. Seven of these 22 patients presented with a
medullary thyroid carcinoma, all other patients showed C-cell
hyperplasia. Patients with medullary thyroid carcinoma
showed higher unstimulated (212 pg/ml (36–577) vs
42 pg/ml (17–150); Po0.001) and higher maximum
pentagastrin-stimulated calcitonin concentrations (862 pg/ml
(431–2423) vs 141 pg/ml (102–471); Po0.001) as compared to
patients with C-cell hyperplasia. The sensitivity (100%) and
specificity (93%) estimates suggested that a maximum
pentagastrin-stimulated calcitonin concentration greater
than 400 pg/ml indicates the presence of medullary thyroid
carcinoma in patients with CKD. Receiver-operating
characteristic (ROC) analysis revealed an area under the
ROC plot of 0.99 for maximum pentagastrin-stimulated
calcitonin concentrations. A maximum pentagastrin-
stimulated calcitonin concentration greater than 400 pg/ml
appears to be a clinically meaningful threshold for
thyroidectomy.
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The C cells of the thyroid gland produce calcitonin in
response to hypercalcemia, thus contributing to calcium
homeostasis.1 A calcitonin level greater than 10 pg/ml and an
increase of calcitonin in response to stimulation with
pentagastrin above 100 pg/ml (positive pentagastrin test)
may indicate the presence of medullary thyroid carcinoma.
Total thyroidectomy is recommended in such cases.2 Benign
C-cell hyperplasia, however, may also be associated with
elevated calcitonin concentrations.
Among patients with chronic kidney disease (CKD), the
calcitonin concentration is elevated in about 30%.3–6 It is
currently not known which level of pentagastrin-stimulated
calcitonin indicates medullary thyroid carcinoma, or reflects
only C-cell hyperplasia and secondary hypercalcitoninemia
in CKD. Recently, we demonstrated that pentagastrin-
stimulated calcitonin levels of around 100 pg/ml normalize
after successful kidney transplantation.7 We then hypothe-
sized that pentagastrin-stimulated calcitonin concentrations
far above 100 pg/ml may not necessarily reflect the presence
of medullary thyroid carcinoma in CKD patients and pointed
to the need for further studies that examine calcitonin levels
in CKD patients with histologically proven medullary thyroid
carcinoma or C-cell hyperplasia.
We examined CKD patients of our institution who
underwent total thyroidectomy and tested the diagnostic
performance of basal and pentagastrin-stimulated calcitonin
levels for differentiating medullary thyroid carcinoma and
C-cell hyperplasia.
RESULTS
Patients
In the years from 1997 to 2004, 180 CKD patients who
presented with an elevated calcitonin level had a pentagastrin
stimulation test. Forty patients showed a maximum penta-
gastrin-stimulated calcitonin concentration greater than
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100 pg/ml, and 22 patients had a total thyroidectomy (for
details of patient flow, see Figure 1).
Important demographic data and characteristics of the 22
patients with thyroidectomy are indicated in Table 1. At the
time of calcitonin screening, nine patients were on dialysis
(for 1.4 years (0.1–7.8), seven had a kidney graft (first renal
replacement therapy was 7.3 years (2.4–10.5) ago), and six
patients not on renal replacement therapy had CKD stage
3–5. Thyroid nodules or diffuse enlargement were palpable in
six patients, and detected by ultrasonography in further eight
patients. Calcitonin concentrations at screening and the basal
and maximum pentagastrin-stimulated calcitonin concentra-
tions of the entire cohort are indicated in Table 2.
Surgery
Total thyroidectomy with central and bilateral dissection of
cervical lymph nodes was performed in all patients 3.3
(0.2–40) months after the positive pentagastrin stimulation
test. In seven patients, thyroidectomy was combined with
total removal of the parathyroid glands and autotransplanta-
tion of one gland in the forearm, in 10 patients with subtotal
removal of the parathyroid glands, and five patients had no
surgery of the parathyroid glands.
Histological findings
Seven of the 22 patients undergoing thyroidectomy presented
with a medullary thyroid carcinoma (Figure 2a), all other
patients showed C-cell hyperplasia (Figure 2b and c).
Characteristics of all patients with medullary thyroid
carcinoma are indicated in Table 3. Lymph node metastases
of medullary thyroid carcinoma were found in one patient
(two out of 72 examined lymph nodes). There was no sign of
distant metastases in any of the patients. No medullary
thyroid carcinoma was found in patients after kidney
transplantation. None of the patients with medullary thyroid
carcinoma had germline mutations of the ret protooncogene.
Pentagastrin stimulation of calciton in 
180 patients with CKD
Maximum stimulated calcitonin
>100 pg /ml
40 patients
22 patients
7 patients
2 patients with CKD stage 4
4 patients with CKD stage 5 D
1 patient with CKD stage 5
1 patient with CKD stage 3
5 patients with CKD stage 3 T
2 patients with CKD stage 4 T
5 patients with CKD stage 5 D
2 patients with CKD stage 5
Thyroidectomy No surgery
11 due to comorbidity
7 patients refused
C-cell hyperplasia
15 patients
Medullary thyroid carcinoma
Figure 1 | Flow of patients with CKD and elevated calcitonin levels. T, transplantation, D, dialysis.
Table 1 | Demographic and clinical characteristics of 22
patients with CKD at the time point of calcitonin screening
who later had a pentagastrin-stimulated calcitonin greater
than 100 pg/ml and total thyroidectomy
Median
(minmax)/
Count
(frequency)
Age (years) 53 (18–72)
Gender (male) 21
Current renal function/RRT modality
Hemodialysis 7 (32)
Peritoneal dialysis 2 (9)
Transplantation (eGFR: 44 ml/min/1.73 m2; 20–59) 7 (32)
CKD (eGFR: 18 ml/min/1.73 m2; 12–45) 6 (27)
Native kidney disease
Glomerulonephritis 4 (18)
Diabetic nephropathy 3 (14)
Polycystic kidney disease 2 (9)
Others 9 (41)
Unknown 4 (18)
Calcitonin (pg/ml) 60 (17–577)
Parathyroid hormone (pg/ml) 180 (45–1300)
Calcium (mmol/l) 2.3 (2.10–2.69)
Phosphorus (mmol/l) 1.6 (0.81–2.82)
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; RRT, renal
replacement therapy.
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Seven out of 22 patients had incidental papillary carcino-
mas of the thyroid glands (three of them accompanied
medullary thyroid carcinomas). Lymph node metastases of
papillary thyroid carcinoma were found in five patients (no
distant metastases). For further details, see Table 3.
Calcitonin concentrations in patients with medullary thyroid
carcinoma or C-cell hyperplasia
Pentagastrin-stimulated calcitonin concentrations of patients
with medullary thyroid carcinoma and of patients with C-cell
hyperplasia are shown in Figure 3a and b. Patients presenting
with medullary thyroid carcinoma showed higher unstimu-
lated (Po0.001) and higher maximum pentagastrin-stimu-
lated calcitonin concentrations (Po0.001) as compared to
patients with C-cell hyperplasia (Table 2).
Receiver-operating characteristic analysis
Receiver-operating characteristic (ROC) analysis revealed an
area under the ROC plot of 0.93 for unstimulated and of 0.99
for maximum pentagastrin-stimulated calcitonin concentra-
tions. The ROC curves are shown in Figure 4. Sensitivities
and specificities for different diagnostic thresholds of unstimu-
lated and pentagastrin-stimulated calcitonin concentrations
are indicated in Table 4 and 5.
Follow-up of patients without thyroidectomy
Eighteen patients with a positive pentagastrin stimulation
test were not referred to surgery. Seven of these patients
refused surgery and 11 had comorbid conditions precluding
thyroid surgery. Meanwhile, five patients died, all because of
cardiovascular comorbidity (aged 57–93 years), two with
stable and three without follow-up of unstimulated calcito-
nin concentrations.
Thirteen patients had repeated pentagastrin stimulation
tests with basically same results. Maximum stimulated
calcitonin concentration at study time point was 168777
and 153772 pg/ml at follow-up investigation 1.1 years later
(for further details, see Table 6). In none of the patients, a
clinical sign of medullary thyroid carcinoma was apparent.
One patient (Table 6, ID 7) who primarily refused surgery
had thyroidectomy 1.2 years after the first pentagastrin
stimulation test. The histology revealed a neoplastic C-cell
hyperplasia.
DISCUSSION
We provide evidence that patients with CKD and medullary
thyroid carcinoma have higher unstimulated and higher
pentagastrin-stimulated serum calcitonin concentrations
than patients with CKD and C-cell hyperplasia. A maximum
pentagastrin-stimulated calcitonin concentration exceeding
400 pg/ml in patients with CKD indicates the presence
of medullary thyroid carcinoma, whereas in patients with
CKD and a maximum pentagastrin-stimulated calcitonin
Table 2 | Comparison of CKD patients with medullary thyroid
carcinoma or with C-cell hyperplasia at the time of calcitonin
screening, and results of pentagastrin stimulation
Median (min–max)/Count
MTC (n=7) CCH (n=15)
Age (years) 56 (48–72) 53 (18–65)
Gender (male) 6 15
CT at screening (pg/ml) 212 (36–577) 42 (17–150)*
CT at baseline (pg/ml) 311 (40–545) 35 (22–163)**
CT maximum stimulated (pg/ml) 862 (431–2423) 141 (102–471)***
CCH, C-cell hyperplasia; CKD, chronic kidney disease; CT, calcitonin; MTC, medullary
thyroid carcinoma.
*Po0.001, **Po0.001, *** Po0.001.
a
b
c
Figure 2 | Thyroid pathology. (a) High power field showing solid
nests and columns of typical small round cells of a medullary thyroid
carcinoma (hematoxylin and eosin (H&E), original magnification
 100). (b) Low power view showing nodular C-cell hyperplasia
surrounded by unchanged follicles and colloid of the thyroid gland
(H&E, original magnification  40). (c) Same view of C-cell hyperplasia
with calcitonin staining (immunostain, original magnification  40).
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concentration of less than 400 pg/ml, the presence of C-cell
hyperplasia is likely.
Medullary thyroid carcinomas derive from the calcitonin-
secreting thyroid C cell. Twenty percent occur as inherited
syndromes, including multiple endocrine neoplasia type 2A,
multiple endocrine neoplasia type 2B, and familial non-
multiple endocrine neoplasia medullary thyroid carcinoma,8
whereas the majority occurs as sporadic disease (80%). C-cell
pathology, including physiologic/reactive C-cell hyperplasia,
neoplastic C-cell hyperplasia, and medullary microcarcino-
ma, can be detected biochemically by measuring calcitonin
serum concentrations, both with and without pentagastrin
Table 3 | Pathology of the thyroid gland in 22 chronic kidney disease patients
Nodule size
by
sonography C cells
Thyroid pathology
Patient
number
Age
(years) Sex CKD stage
Palpable
thyroid
abnormality
(Maximum
diameter
(mm))
(Count (per
low-power
field))
Medullary C-cell
pathology (tumor stages
or type of CCH)
Incidental
papillary tumors
(tumor stages)
1 18 M 5 Soft nodules 29 158 Diffuse pT1b pN1b M0
2 22 M 5D Normal — 111 Diffuse —
3 31 M 4T Normal 6 764 Diffuse and nodular —
4 42 M 5D Normal ND 386 Neoplastic —
5 42 M 5D Normal 6 305 Diffuse and nodular-
neoplastic
pT2a pN1b M0
6 49 M 3T Normal — 506 Nodular-neoplastic —
7 52 M 4T Small nodules 11 264 Diffuse —
8 53 M 3 Normal — 851 Neoplastic pT4a pN1b M0
9 54 M 3T Enlarged, cystic 56 465 Diffuse and nodular —
10 55 M 5 Normal 6 658 Neoplastic pT1a N0 M0
11 59 M 3T Normal 10 269 Neoplastic —
12 59 M 5D Normal 5 354 Nodular —
13 61 M 5D Small nodules 20 671 Neoplastic —
14 64 M 3T Normal 5 645 Diffuse, nodular-neoplastic —
15 65 M 3T Normal ND 786 Nodular-neoplastic —
16 48 M 5D Normal ND 807 *pT1b pN0 M0 —
17 52 M 5D Normal 7 89 *pT1a pN0 M0 pT1b pN1a M0
18 53 M 5 Normal — 957 *pT1a pN0 M0 —
19 56 M 5D Normal 3 477 *pT1a pN0 M0 PT1a pN1b M0
20 60 M 4T Normal — ND pT1b pN0 M0 —
21 70 M 5D Enlarged, cystic 42 63 *pT1a pN1a M0 —
22 72 F 4 Multiple
nodules
15 25 pT2 pN0 M0 pT1b pN0 M0
CCH, C-cell hyperplasia; CKD, chronic kidney disease; D, dialysis; F, female; M, male; ND, not done; T, transplantation.
*Patients presenting with medullary mircrocarcinoma, that is, maximum diameter of tumor o10 mm.
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Figure 3 | Basal and pentagastrin-stimulated serum calcitonin concentrations of 22 patients with CKD presenting with either
C-cell hyperplasia or medullary thyroid carcinoma. (a) Patients with CKD stage 5 D either on hemodialysis (J) or peritoneal dialysis (n).
T, transplantation, D, dialysis. (b) Patients with CKD stages 3–5 (&) or CKD stage 3–4 T (*).
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and/or calcium stimulation. Calcitonin testing, together with
mutational analysis of RET, is a well-established tool for the
management of families with hereditary forms of medullary
thyroid carcinoma or for follow-up after surgery for sporadic
medullary thyroid carcinoma.9–11 In contrast, the role of
routine measurement of calcitonin in patients with thyroid
nodules, or screening of other patient populations is a matter
of debate. Although recommended by several experts, the
cost-effectiveness of calcitonin screening is not proven and
the results can be misleading.11–14 Nevertheless, surgical
treatment was recommended if calcitonin levels surpass
100 pg/ml.2,15
The situation of calcitonin testing in patients with CKD is
even more puzzling. Up to 30% of patients with advanced
renal insufficiency present with elevated calcitonin
concentrations3–6 and calcitonin stimulation with pentagas-
trin or calcium revealed controversial results in such
patients.3–6,16 A recent study examined kidney transplant
wait-listed patients with CKD stage 4 and stage 5, who,
in several cases, presented with elevated pentagastrin-
stimulated calcitonin levels close to 100 pg/ml (a suggested
threshold for thyroid surgery). After successful kidney
transplantation, unstimulated and pentagastrin-stimulated
calcitonin concentrations returned to normal in almost
all patients.7 Thus, it was concluded that calcitonin elevation
not necessarily reflects accumulation of calcitonin owing
to decreased renal clearance, but may be due to increased
calcitonin secretion related to C-cell hyperplasia in uremia
(secondary hypercalcitoninemia). We mentioned that
calcitonin levels close to 100 pg/ml obviously do not indicate
presence of medullary thyroid carcinoma in patients
with advanced kidney disease. We also pointed to the
need for studies correlating elevated stimulated and un-
stimulated calcitonin levels with histologically proven C-cell
hyperplasia and medullary thyroid carcinoma in such
patients.7
In the present study, we examined the diagnostic accuracy
of unstimulated and pentagastrin-stimulated calcitonin levels
for differentiating medullary thyroid carcinoma and C-cell
hyperplasia in patients with CKD and advanced renal failure
(estimated glomerular filtration rate o60 ml/min/1.73 m2 or
dialysis), who had a total thyroidectomy because of a positive
pentagastrin stimulation test. The histological examination of
total thyroidectomy specimens of 22 patients showed seven
cases with medullary thyroid carcinoma. Patients of our
study who had histologically proven medullary thyroid
carcinoma had higher calcitonin concentrations than patients
presenting with C-cell hyperplasia.
ROC analysis of basal and maximum stimulated calcitonin
concentration suggested a diagnostic accuracy, that is, the
ability to discriminate between medullary thyroid carcinoma
and C-cell hyperplasia of 50–150 pg/ml for basal calcitonin
concentration and 400–500 pg/ml for maximum stimulated
calcitonin concentration. The area under the ROC plot was
excellent in both instances. In patients on dialysis, however,
unstimulated calcitonin concentrations seem to be higher
than in patients with CKD without need for dialysis. As one
can see from Figure 3a, medullary thyroid carcinoma was
found in patients on dialysis only when unstimulated
calcitonin concentration exceeded 250 pg/ml. Presuming the
patient’s general condition is suitable for surgery, it seems
reasonable to perform a thyroidectomy in patients with a
pentagastrin-stimulated calcitonin concentrations greater
than 400 pg/ml. Follow-up of patients with positive
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Figure 4 | ROC curves of unstimulated and maximum
pentagastrin-stimulated calcitonin concentrations.
Table 4 | Sensitivity and specificity estimates of different
basal calcitonin threshold levels for presence of medullary
thyroid carcinoma.
Basal calcitonin
(pg/ml)
Sensitivity
(95% CI)
Specificity
(95% CI)
10 100 (59–100) 0 (0–22)
30 100 (59–100) 27 (8–55)
40 100 (59–100) 60 (32–84)
50 86 (42–100) 67 (38–88)
100 86 (42–100) 87 (60–98)
150 71 (29–96) 93 (68–100)
200 71 (29–96) 100 (78–100)
300 57 (18–90) 100 (78–100)
400 29 (4–71) 100 (78–100)
500 14 (0–58) 100 (78–100)
Table 5 | Sensitivity and specificity estimates of different
maximum pentagastrin-stimulated calcitonin threshold
levels for presence of medullary thyroid carcinoma
Maximum calcitonin
(pg/ml)
Sensitivity
(95% CI)
Specificity
(95% CI)
100 100 (59–100) 0 (0–22)
200 100 (59–100) 60 (32–84)
300 100 (59–100) 87 (60–98)
400 100 (59–100) 93 (68–100)
500 86 (42–100) 100 (78–100)
800 71 (29–96) 100 (78–100)
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pentagastrin stimulation test not undergoing thyroidectomy
showed stable calcitonin concentrations. This finding further
supports the presence of secondary hypercalcitoninemia in
patients with CKD.
In three patients with medullary thyroid carcinoma and in
four patients with C-cell hyperplasia, we found an incidental
papillary thyroid microcarcinoma in the surgical specimens.
The relationship between incidental papillary microcarcino-
ma and clinical papillary thyroid carcinoma is not clear, but
both entities may differ in terms of etiology and biologic
behavior. Autopsy studies showed that occult papillary
thyroid carcinoma is present in 1–36% of patients who had
no known history for thyroid disease.17 Therefore, a more
conservative approach to manage incidental papillary carci-
noma was suggested to be wise.17 In patients without CKD,
co-occurrence of medullary thyroid carcinoma with papillary
microcarcinoma was reported recently.18 However, in a large
series from Italy the presence of papillary microcarcinoma
did not alter the clinical course as compared to the
occurrence of medullary thyroid carcinoma alone.18
The small sample size of patients who underwent thyroid
surgery is a limitation to our study. Nevertheless, this analysis
represents the largest case series of CKD patients presenting
with medullary thyroid carcinoma. A further limitation to
our study might be the under-representation of women.
There exists the possibility of overseeing women with C-cell
hyperplasia and/or medullary thyroid carcinoma when an
unstimulated calcitonin concentration threshold of 10 pg/ml
is used as an indication for pentagastrin stimulation instead
of the upper limit of the reference interval.
This study of patients with CKD for the first time provides
an analysis of diagnostic accuracy of basal and pentagastrin-
stimulated calcitonin levels for medullary thyroid carcinoma
in patients with CKD. Our data suggest that a maximum
pentagastrin-stimulated calcitonin concentration greater
than 400 pg/ml indicates the presence of medullary thyroid
carcinoma in patients with CKD.
MATERIALS AND METHODS
Study design
In patients with CKD, serum calcitonin concentrations are
determined as standard of care at our institution to exclude the
presence of medullary thyroid carcinoma. At calcitonin concentra-
tions above 10 pg/ml (close or greater than 30 pg/ml in dialysis
patients), a pentagastrin stimulation test is recommended. If the
maximum increase of serum calcitonin after pentagastrin stimula-
tion exceeds 100 pg/ml, total thyroidectomy has been performed in
the past. We included in this analysis all CKD patients of our
institution who had a positive pentagastrin stimulation test and
subsequent thyroidectomy and compared basal and pentagastrin-
stimulated calcitonin levels in patients presenting with either
medullary thyroid carcinoma or with C-cell hyperplasia.
Calcitonin screening
Routine calcitonin screening was done together with parathyroid
hormone measurements in patients on hemodialysis every 3
months. In patients on peritoneal dialysis, it was done once a year.
In CKD patients stage 3–5, the decision was made by the individual
physician in charge. In case the patient was listed for a kidney
transplantation or had a kidney transplantation, calcitonin was
measured once a year.
For the pentagastrin stimulation test, fasting blood was drawn
before and 2, 5, and 10 min after an intravenous administration of a
bolus of 0.5 mg/kg body weight pentagastrin (Peptavlon, Astra-
Zeneca, Vienna, Austria) for the determination of serum calcitonin
levels. The pentagastrin stimulation test was performed in the
morning either before the hemodialysis session or on the dialysis-
free day. In patients treated with peritoneal dialysis, the test was
done in the morning after the first change of the bag. The thyroid
gland was examined by palpation and/or ultrasound in every patient
who received pentagastrin stimulation.
Measurements
Blood chemistry (serum calcium, phosphorus, and creatinine) was
determined in a clinical laboratory at the Medical University Vienna.
Overall, renal function (estimated glomerular filtration rate;
ml/min/1.73 m2) was estimated from serum creatinine levels using
the short modification of diet in renal disease formula19 to classify
Table 6 | Follow-up on pentagastrin stimulation in 13 patients with CKD who denied recommended surgery or who were not
eligible for surgery due to comorbidity
First calcitonin stimulation (pg/ml) Second calcitonin stimulation (pg/ml)
ID
Age
(years) 0 2 min 5 min 10 min Max 0 2 min 5 min 10 min Max
Time between
both tests (years)
1 77 23 138 113 85 138 22 57 58 47 58 0.
2 52 22 90 101 85 101 28 114 113 113 114 0.8
3 47 30 102 88 75 102 19 84 81 56 84 1.1
4 59 41 98 90 62 98 38 116 116 78 116 0.2
5 61 50 52 106 87 106 23 107 90 66 107 2.5
6 47 55 229 225 138 229 57 263 269 251 269 0.7
7 54 26 128 112 79 128 32 124 110 82 124 1.2
8 70 38 151 199 14 199 61 262 227 183 262 0.5
9 58 40 190 156 114 190 41 165 130 109 165 0.6
10 63 50 98 309 282 309 44 87 218 206 218 0.5
11 44 66 174 150 116 174 65 153 124 116 153 0.6
12 38 17 100 91 54 100 16 80 65 41 80 4.1
13 24 58 315 265 192 315 58 295 240 196 240 1.1
CKD, chronic kidney disease.
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CKD stages.20 Intact parathyroid hormone serum level was deter-
mined by a commercially available Radio immuno assay (Nichols
Institute Diagnostics, San Clemente, CA, USA).
During the time of this study, three assays were used for
measurement of calcitonin serum concentrations.21 All three assays
used monoclonal mouse antibodies: 1. January 1997 – May 1999:
Calcitonin immunoradiometric assay (CIS Bio International,
Gif-Sur-Yvette, France) (analytical sensitivity: 1–4 pg/ml; coefficient
of variation: 3–15%) is using two monoclonal mouse antibodies
(reference interval: femaleso10 pg/ml; maleso10 pg/ml). 2. June
1999 –March 2000: Medgenix CT-U.S.-IRMA kit (BioSource Europe
S.A., Nivelles, Belgium) is an immunoradiometric assay (analytical
sensitivity: 1–2 pg/ml; coefficient of variation: 3–12%) using two
monoclonal mouse antibodies (reference interval: femaleso10 pg/
ml; maleso10 pg/ml). 3. April 2000 – December 2004: Nichols
Advantage Calcitonin Assay (Nichols Institute Diagnostics, San
Clemente, CA, USA) is an immunochemiluminometric assay
(analytical sensitivity: 1 pg/ml; coefficient of variation: 8%) using
two monoclonal mouse antibodies (reference interval: female-
so4.6 pg/ml; maleso11.5 pg/ml). Independently from the differ-
ences in the reference intervals of the three assays used, a
pentagastrin test was recommended when basal calcitonin concen-
trations exceeded 10 pg/ml.15 The upper limit of normal for
pentagastrin-stimulated calcitonin in 19 healthy volunteers was
found to be 43.0 pg/ml for males and 36.8 pg/ml for females.22
Total thyroidectomy
After dissection of both recurrent nerves, a systematic microdissec-
tion of the lymph node compartment from the upper thoracic outlet
up to the larynx was performed. In patients with tertiary
hyperparathyroidism, a total parathyroidectomy with immediate
autotransplantation or subtotal parathyroidectomy with removal of
three and a half glands including transcervical thymectomy and
cryopreservation of parathyroid tissue was performed.2
Histology
Surgical specimens from total thyroidectomy and lymphadenectomy
by modified radical neck dissections were blocked entirely. Tissue
was processed by standard methods, paraffin embedded and cut in
sections of 5 mm. All specimens were stained with hematoxylin and
eosin, and calcitonin immunostaining was performed using the
avidin–biotin–peroxidase technique with a commercially available
antibody (Chemicon, Temuecula, CA, USA).23 C-cell hyperplasia
was diagnosed when at least one field at an  100 magnification
contained more than 50 C cells in each thyroid lobe.24 Medullary
thyroid carcinoma and papillary thyroid carcinoma were diag-
nosed24 and staged according to the International Union of Cancer
TNM classification (5th edition, 1997).
Statistical analysis
Continuous data are summarized as medians and full ranges,
categorical data are described by counts and frequencies. We
compared basal and stimulated calcitonin serum concentrations of
patients with medullary thyroid carcinoma and of patients with
C-cell hyperplasia by Mann–Whitney-U test.
We used ROC analysis to describe the performance of basal and
pentagastrin-stimulated calcitonin levels for differentiating medul-
lary thyroid carcinoma and C-cell hyperplasia. The area under the
ROC plot was calculated as an index of diagnostic accuracy. The
variability of sensitivity/specifity estimates is indicated by 95% exact
confidence intervals. SAS (Version 9.1, 2002–2003, SAS Institute
Inc.) and SPSS (Version 12.0, 2003, SPSS Inc.) were used for all
analyses.
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